{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/urticaria/prescribing-information/sedating-antihistamines/","result":{"pageContext":{"chapter":{"id":"8888f0f6-7dd8-55fb-afc0-9e5df55b825a","slug":"sedating-antihistamines","fullItemName":"Sedating antihistamines","depth":2,"htmlHeader":"<!-- begin field 11be5f7d-6598-4e24-a334-a73d00a1f8f5 --><h2>Sedating antihistamines</h2><!-- end field 11be5f7d-6598-4e24-a334-a73d00a1f8f5 -->","summary":"","htmlStringContent":"<!-- begin item 34217192-6860-4b36-8e5d-a73d00a1f90c --><!-- end item 34217192-6860-4b36-8e5d-a73d00a1f90c -->","topic":{"id":"bfdbbcbf-5a56-51b8-b0aa-78a059b4cfec","topicId":"73ccd3ba-b5a5-4a3c-98b2-d838dd8a3c58","topicName":"Urticaria","slug":"urticaria","lastRevised":"Last revised in March 2020","chapters":[{"id":"7068e840-7bdb-5596-a56f-1c930bd4b8c4","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"d6e4cfbd-5e36-5755-a780-8091e4b5f146","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"9dde1c08-758f-55bb-b187-0203ded94048","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"3daa7b54-d234-587b-8a56-1bb5cae1efe4","slug":"changes","fullItemName":"Changes"},{"id":"54c42276-0c06-5c18-825f-3c440cb30dfe","slug":"update","fullItemName":"Update"}]},{"id":"5cff12c3-445b-5613-bf5d-dc48effe6502","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"9abed54c-a9ed-58d4-bfce-3f0dddd49698","slug":"goals","fullItemName":"Goals"},{"id":"c2f713b4-e2ec-5e5e-be8f-5c4285be0b6e","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"e829abf6-8412-500f-9425-647958addf97","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"92b040fe-6318-560a-9ae0-6f98a6aa9c09","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"2d2f38df-88c4-5895-915d-199eefc9b02a","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"d51180cd-461f-58ad-8f03-20d63965abfb","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"a7fce165-b445-5aa6-9ec9-6ec8016f4bee","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"a5d17f35-ddfe-5931-bfe4-b7dc039baea0","slug":"definition","fullItemName":"Definition"},{"id":"90888c1e-cd37-5fdf-9d0d-b71e51bf56c3","slug":"causes-trigger-factors","fullItemName":"Causes/trigger factors"},{"id":"76d2cc5e-4a3e-5032-8eed-d4010ace1ae7","slug":"prevalence","fullItemName":"Prevalence"},{"id":"507a6931-af71-54ae-a8e7-2b4393c2a41b","slug":"complications","fullItemName":"Complications"},{"id":"091f4740-5801-5ac0-83bd-a7ebbc2a2848","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"fc3a9cf3-3dd4-5456-94e1-90c38c83a0b1","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"513fb45b-36c0-59b5-8f88-13b10509caee","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"e2100cac-0eb7-55e6-b138-9cbc110f1b71","slug":"investigations","fullItemName":"Investigations"},{"id":"2da7bf77-7798-5632-97d4-64d5463f8cde","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"1a1cabda-9d82-5131-8852-db2d844e0b46","fullItemName":"Management","slug":"management","subChapters":[{"id":"f797a7bd-9ca9-523b-8f1e-e2afc927c4ab","slug":"managing-urticaria","fullItemName":"Scenario: Managing urticaria"}]},{"id":"3c7854e6-2fe5-5632-9b63-69f2773b7dd1","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"71f6ce5f-ac94-5ef4-9a02-0aa362883a44","slug":"non-sedating-antihistamines","fullItemName":"Non-sedating antihistamines"},{"id":"8888f0f6-7dd8-55fb-afc0-9e5df55b825a","slug":"sedating-antihistamines","fullItemName":"Sedating antihistamines"},{"id":"b8336773-e3de-5ec0-a85b-93fd72ff7869","slug":"oral-corticosteroids","fullItemName":"Oral corticosteroids"}]},{"id":"c88fe5a9-a559-5661-9a1f-e0ee93078a4d","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"e9950b4f-8af1-5d4b-b531-431ac4a731bb","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"729aa2a2-070b-51ed-9ecf-c29549914b66","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"a30a2a17-7629-5022-a313-848d8264fb35","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"f6d1c75a-6a3d-5326-97ca-baff36370740","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"dd5a897e-e7d5-5c98-88b6-35014f9a5dde","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"6d27a969-ded2-5d9d-9321-f65e47426edf","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"0d45859d-1b50-538f-84fa-568f43b5c283","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"3c7854e6-2fe5-5632-9b63-69f2773b7dd1","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"1fa8dace-4503-522f-8c96-3ee19527e773","slug":"choice-of-antihistamine","fullItemName":"Choice of antihistamine","depth":3,"htmlHeader":"<!-- begin field defc26ad-8276-4368-acbc-a73d00a20e9d --><h3>Which sedating antihistamine should I prescribe?</h3><!-- end field defc26ad-8276-4368-acbc-a73d00a20e9d -->","summary":"","htmlStringContent":"<!-- begin item 4ab8caa7-f3f5-4eea-9d1a-a73d00a20e7c --><!-- begin field 63dbd311-47a7-4e58-83bc-a73d00a20e9d --><ul><li><strong>For most adults and children (aged 1 month and older), </strong>chlorphenamine is a usual choice as its long-term safety has been well established. However, any suitable sedating antihistamine can be considered as all are licensed for the treatment of urticaria, and there is no strong evidence that one is more effective than the other.<ul><li><strong>Be aware that </strong>hydroxyzine is associated with a small risk of QT-interval prolongation and Torsade de Pointes and should not be used in people with prolonged QT interval or risk factors for QT prolongation [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">MHRA, 2015</a>]. See the Drug Safety Update <a href=\"https://www.gov.uk/drug-safety-update/hydroxyzine-atarax-ucerax-risk-of-qt-interval-prolongation-and-torsade-de-pointes\" data-hyperlink-id=\"2fad566f-f0d2-4c16-bf4b-a98f01710bd7\">Hydroxyzine (Atarax, Ucerax): risk of QT interval prolongation and Torsade de Pointes</a><strong> </strong>available on the<strong> </strong>Medicines and Healthcare products Regulatory Agency (MHRA) website (<a href=\"https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency\" data-hyperlink-id=\"ab668a69-3642-4c33-9754-a98f01710c17\">www.gov.uk</a>) for more information.</li></ul></li><li><strong>During pregnancy, </strong>oral antihistamines should be avoided where possible, especially during the first trimester. However, if a sedating antihistamine is required, chlorphenamine is recommended [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Zuberbier, 2014</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Powell, 2015</a>].<ul><li>Most manufacturers of antihistamines advise avoiding their use during pregnancy; however, there is no evidence of teratogenicity with their use, except for hydroxyzine where toxicity has been reported with high doses in <em>animal</em> studies.</li><li>The use of sedating antihistamines in the latter part of the third trimester may cause adverse effects in neonates, such as irritability, paradoxical excitability, and tremor [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">BNF 72, 2016</a>].</li></ul></li><li><strong>During breastfeeding,</strong> <a class=\"topic-reference internal-reference\" href=\"/topics/urticaria/prescribing-information/non-sedating-antihistamines/\">non-sedating antihistamines</a> are preferred, but if a sedating antihistamine is indicated, chlorphenamine can be considered.<ul><li>LactMed (a US drugs and lactation database) states that 'small (2 to 4 mg), occasional doses of chlorpheniramine are acceptable during breastfeeding. Larger doses or more prolonged use might cause effects in the infant or decrease the milk supply. Single bedtime doses after the last feeding of the day may be adequate for many women and will minimize any effects of the drug [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">LactMed, 2017</a>]. </li><li>Most antihistamines are present in breast milk (in varying amounts) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">Zuberbier, 2014</a>]. Although not known to be harmful, most manufacturers advise avoiding their use in mothers who are breastfeeding [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">BNF 72, 2016</a>].</li></ul></li></ul><!-- end field 63dbd311-47a7-4e58-83bc-a73d00a20e9d --><!-- end item 4ab8caa7-f3f5-4eea-9d1a-a73d00a20e7c -->","subChapters":[]},{"id":"ed0b8fad-a9a9-5573-bfe9-41fc619ef008","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 9c085342-a686-4431-b5a7-a73d00a22453 --><h3>What are the contraindications and cautions for chlorphenamine?</h3><!-- end field 9c085342-a686-4431-b5a7-a73d00a22453 -->","summary":"","htmlStringContent":"<!-- begin item 23a593f1-45f7-40ea-83b3-a73d00a22479 --><!-- begin field 3305b836-90cc-423c-a08c-a73d00a22453 --><ul><li><strong>Do not prescribe </strong><strong>chlorphenamine to:</strong><ul><li>People with severe hepatic impairment — increased risk of coma.</li></ul></li><li><strong>Prescribe chlorphenamine with caution in:</strong><ul><li>People with:<ul><li>Hepatic impairment.</li><li>Epilepsy — avoid antihistamines if possible as they reduce the seizure threshold.</li><li>Renal impairment.</li><li>Prostatic hypertrophy.</li><li>Urinary retention.</li><li>Severe hypertension or cardiovascular disease.</li><li>Raised intraocular pressure or glaucoma.</li><li>Pyloroduodenal obstruction.</li><li>Asthma, bronchitis, or bronchiectasis.</li></ul></li><li>Children and the elderly (as they are more susceptible to <a class=\"topic-reference internal-reference\" href=\"/topics/urticaria/prescribing-information/sedating-antihistamines/#adverse-effects\">adverse effects</a>) — be aware of a reduced maximum daily <a class=\"topic-reference internal-reference\" href=\"/topics/urticaria/prescribing-information/sedating-antihistamines/#licensed-doses\">dose</a> in children and elderly people.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">ABPI, 2015</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">BNF 72, 2016</a>]</p><!-- end field 3305b836-90cc-423c-a08c-a73d00a22453 --><!-- end item 23a593f1-45f7-40ea-83b3-a73d00a22479 -->","subChapters":[]},{"id":"a5c8cf27-b40d-56d7-8e09-e6eb9af4f122","slug":"licensed-doses","fullItemName":"Licensed doses","depth":3,"htmlHeader":"<!-- begin field 5533a8e2-6067-453b-b22a-a73d00a24596 --><h3>What are the licensed doses of chlorphenamine for the treatment of chronic idiopathic urticaria?</h3><!-- end field 5533a8e2-6067-453b-b22a-a73d00a24596 -->","summary":"","htmlStringContent":"<!-- begin item 2ef81a11-9932-499b-a986-a73d00a245ce --><!-- begin field 0de8ccb4-1260-42d5-8f38-a73d00a24596 --><ul><li><strong>The licensed oral daily doses of chlorphenamine are [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">BNF 73, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">BNF for Children, 2017</a>]:</strong><ul><li>Age 2 years to 5 years - 1 mg every 4-6 hours; maximum of 6 mg daily.<ul><li>Chlorphenamine is not licensed for use in children younger than 1 year [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">ABPI, 2016</a>], but the British National Formulary for Children (BNFC) recommends an unlicensed dose of 1 mg twice daily for children aged 1 month to 23 months [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">BNF for Children, 2017</a>].</li></ul></li><li>Age 6 years to 11 years - 2 mg every 4-6 hours; maximum of 12 mg daily.</li><li>Age 12 years and over (including adults) — 4 mg every 4-6 hours; maximum of 24 mg daily (12 mg daily in elderly people).</li></ul></li><li><strong>For night time use for urticarial symptoms, consider the following doses (using clinical judgement):</strong><ul><li>Age 1 month to 23 months - 1 mg at night.</li><li>Age 2 years to 5 years - 2 mg at night.</li><li>Age 6 years to 11 years - 2 to 4 mg at night.</li><li>Age 12 years and over (including adults) - 4 mg at night.</li></ul></li></ul><!-- end field 0de8ccb4-1260-42d5-8f38-a73d00a24596 --><!-- end item 2ef81a11-9932-499b-a986-a73d00a245ce -->","subChapters":[]},{"id":"2567657b-d08f-5fd6-aa50-0d69159e2128","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 750f9ebe-f7f6-4c21-a84c-a73d00a25612 --><h3>What are the possible adverse effects of chlorphenamine?  </h3><!-- end field 750f9ebe-f7f6-4c21-a84c-a73d00a25612 -->","summary":"","htmlStringContent":"<!-- begin item 3cb09f49-9987-4994-be42-a73d00a256a7 --><!-- begin field b57ccd88-c0d5-4cbd-ba48-a73d00a25612 --><ul><li><strong>Sedating antihistamines (such as </strong><strong>chlorphenamine)</strong> cause sedation in 10–50% of people, which can persist into the next day [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">DTB, 2002</a>]. The sedative effects are enhanced when combined with alcohol.   </li><li><strong>Other adverse effects of chlorphenamine include [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">ABPI, 2015</a>]:</strong><ul><li>Neurological — dizziness, restlessness, psychomotor impairment, and headaches.</li><li>Anticholinergic effects — blurred vision, dry mouth, and urinary retention.</li><li>Skin — urticaria, rash, exfoliative dermatitis, and photosensitivity.</li><li>Gastrointestinal — nausea, vomiting, abdominal pain, diarrhoea, and dyspepsia.</li><li>Cardiovascular — palpitations, tachycardia, and arrhythmias.</li><li>Neuropsychiatric — depressed mood, excitation, irritability, nightmares, and confusion.</li></ul></li><li><strong>Rare adverse effects of antihistamines include</strong> hypotension, extrapyramidal effects, sleep disturbances, tremor, convulsions, hypersensitivity reactions (including bronchospasm, angioedema, and anaphylaxis), blood disorders, liver dysfunction, and angle-closure glaucoma.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">BNF 72, 2016</a>]</p><!-- end field b57ccd88-c0d5-4cbd-ba48-a73d00a25612 --><!-- end item 3cb09f49-9987-4994-be42-a73d00a256a7 -->","subChapters":[]},{"id":"cc60054f-c68a-5d60-a785-d42c2273ecb5","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 3045d31a-319d-4130-be23-a73d00a278ac --><h3>What drug interactions are associated with chlorphenamine?</h3><!-- end field 3045d31a-319d-4130-be23-a73d00a278ac -->","summary":"","htmlStringContent":"<!-- begin item 8510d1be-5f0f-44c8-a4e1-a73d00a27933 --><!-- begin field b9d0bceb-2c4d-4b07-b5f1-a73d00a278ac --><ul><li><strong>Drug interactions associated with </strong><strong>chlorphenamine include:</strong><ul><li><strong>Antidepressants (monoamine oxidase inhibitors [MAOIs], tricyclics, and tricyclic-related):</strong><ul><li>Chlorphenamine is contraindicated in people who have been treated with MAOIs within the last fourteen days, due to the increased antimuscarinic and sedative effects when antihistamines are taken with MAOIs [<a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">ABPI, 2015</a>].</li><li>There is increased antimuscarinic and sedative effects when antihistamines are taken with tricyclics.</li><li>There is possible increased antimuscarinic and sedative effects when antihistamines are taken with tricyclic-related antidepressants.</li></ul></li><li><strong>Phenytoin —</strong> chlorphenamine inhibits phenytoin metabolism and can lead to phenytoin toxicity. If symptoms of toxicity are present (confusion, blurred vision, nystagmus, ataxia, or drowsiness), monitor serum phenytoin levels and reduce the dose if necessary.</li></ul></li><li><strong>Drug interactions associated with all antihistamines include:</strong><ul><li><strong>Alcohol —</strong> increased sedative effect when antihistamines are taken with alcohol (possibly less effect with non-sedating antihistamines).</li><li><strong>Antimuscarinics —</strong> increased risk of antimuscarinic adverse effects when antihistamines are taken with antimuscarinic drugs (dosage adjustment may be required).<ul><li>Note that many drugs have antimuscarinic effects. Concurrent use of two or more of such drugs can increase adverse effects, such as dry mouth, urine retention, and constipation. Concurrent use can also lead to confusion in the elderly. Interactions do not generally apply to inhaled antimuscarinics.</li></ul></li><li><strong>Anxiolytics, hypnotics, and opioids —</strong> increased sedative effect when antihistamines are taken with anxiolytics and hypnotics.</li><li><strong>Betahistine —</strong> antihistamines theoretically antagonize the effects of betahistine.</li><li><strong>Midodrine —</strong> avoidance of antihistamines advised by manufacturer of midodrine.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/urticaria/references/\">BNF 72, 2016</a>]</p><!-- end field b9d0bceb-2c4d-4b07-b5f1-a73d00a278ac --><!-- end item 8510d1be-5f0f-44c8-a4e1-a73d00a27933 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}